Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors

Virology

Volumn 464-465, Issue 1, 2014, Pages 296-311

  Long, Deborah ^a   Skoberne, Mojca ^a   Gierahn, Todd M ^a,b   Larson, Shane ^a   Price, Jessica A ^a   Clemens, Veronica ^a   Baccari, Amy E ^a   Cohane, Kenya P ^a,c   Garvie, Danielle ^a   Siber, George R ^a   Flechtner, Jessica B ^a  

^a Cambridge Discovery Park   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Covance Laboratories ^*  (United States)

Author keywords

Antigens; Herpes simplex virus; Recurrent genital herpes; T cells

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; T LYMPHOCYTE ANTIGEN; EPITOPE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; ASYMPTOMATIC INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HIGH THROUGHPUT SCREENING; HUMAN; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEOMICS; RECURRENT INFECTION; SYMPTOM; YOUNG ADULT; GENETICS; IMMUNOLOGY; VIROLOGY;

ADULT; AGED; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; EPITOPES, T-LYMPHOCYTE; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84905662128     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.07.018     Document Type: Article

References (73)

1. Andersen S., Ericsson M., Dai H.Y., Pena-Diaz J., Slupphaug G., Nilsen H., Aarset H., Krokan H.E. Monoclonal B-cell hyperplasia and leukocyte imbalance precede development of B-cell malignancies in uracil-DNA glycosylase deficient mice. DNA Repair 2005, 4(12):1432-1441.
2. Ayyoub M., Migliaccio M., Guillaume P., Lienard D., Cerottini J.-C., Romero P., Levy F., Speiser D.E., Valmori D. Lack of tumour recognition by nTERT peptide 540-548 specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 2001, 31:2642-2651.
3. Banks T.A., Jenkins F.J., Kanangat S., Nair S., Dasgupta S., Foster C.M., Rouse B.T. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge. Virology 1994, 200(1):236-245.
4. Belshe R.B., Leone P.A., David I., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., Gorfinkel I., Ashley Morrow R.L., Ewell M.G., Stokes-Riner A., Dubin G., Heineman T.C., Schulte J.M., Deal C.D. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 2012, 366:34-43.
5. Belshe R.B., Heineman T.C., Bernstein D.I., Bellamy A.R., Ewell M., van der Most R., Deal C.D. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J. Infect. Dis. 2013, 209:823-836.
6. Braun R.P., Payne L.G., Dong L. Characterization of the IFN-g T cell responses to immediate early antigens in humans with genital herpes. Virol. J. 2006, 3(1):54.
7. Brown Z.A., Benedetti J., Ashley R., Burchett S., Selke S., Berry S., Vontver L.A., Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N. Engl. J. Med. 1991, 324(18):1247-1252.
8. Chadha P., Han J., Starkey J.L., Wills J.W. Regulated interaction of tegument proteins UL16 and UL11 from herpes simplex virus. J. Virol. 2012, 86(21):11886-11898.
9. Chiu C., McCausland M., Sidney J., Duh F.-M., Rouphael N., Mehta A., Mulligan M., Carringfon M., Wieland A., Sullivan N.L., Weinberg A., Levin J.M., Pulendran B., Peters B., Sette A., Ahmed R. Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. PLoS Pathog. 2014, 10:3.
10. Chentoufi A.A., Binder N.R., Berka N., Durand G., Nguyen A., Bettahi I., Maillere B., BenMohamed L. Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B. J. Virol. 2008, 82(23):11792-11802.
11. Cohen J. Immunology. Painful failure of promising genital herpes vaccine. Science 2010, 330(6002):304.
12. Corey L. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection:two randomized controlled trials. JAMA 1999, 282:331-340.
13. Cunningham A.L., Diefenbach R.J., Miranda-Saksena M., Bosnjak L., Kim M., Jones C., Douglas M.W. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 2006, 194:S11-S18.
14. Cunningham A.L., Merigan T.C. gamma Interferon production appears to predict time of recurrence of herpes labialis. J. Immunol. 1983, 130(5):2397-2400.
15. Dasgupta G., Chentoufi A.A., Kalantari M., Falatoonzadeh P., Chun S., Lim C.H., Felger P.L., Davies D.H., BenMohamed L. Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J. Virol. 2012, 86:4358-4369.
16. Dolan A., Jamieson F.E., Cunningham C., Barnett B.C., McGeoch D.J. The genome sequence of herpes simplex virus type 2. J. Virol. 1998, 72:2010-2021.
17. Ghiasi H., Kaiwar R., Slanina S., Nesburn A.B., Wechsler S.L. Expression and characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein L. Arch. Virol. 1994, 138:199-212.
18. Gierahn T. The T cell responses generated during Chlamydia trachomatis infection: identification of novel antigens and characterization of their presentation by infected host cells 2007, (PhD dissertation), Harvard University, Division of Medical Sciences, Cambridge, MA.
19. Goldsmith K., Chen W., Johnson D.C., Hendricks R.L. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J. Exp. Med. 1998, 187(3):341-348.
20. Green J.A., Weiss P.N., Yeh T.J., Spruance S.L. Immune-specific interferon production by peripheral blood mononuclear leukocytes from patients with primary and recurrent oro-labial herpes simplex virus infections. J. Med. Virol. 1985, 16(3):297-305.
21. Grubaugh D., Flechtner J.B., Higgins D.E. Proteins as T cell antigens:methods for high-throughput identification. Vaccine 2013, 31:3805-3810.
22. Halford W.P., Geltz J., Gershburg E. Pan-HSV-2 IgG antibody in vaccinated mice and Guinea pigs correlates with protection against Herpes simplex virus 2. PLoS One 2013, 8(6):e65523.
23. Han J., Chadha P., Starkey J.L., Wills J.W. Function of glycoprotein E of herpes simplex virus requires coordinated assembly of three tegument proteins on its cytoplasmic tail. Proc. Natl. Acad. Sci. 2012, 109(48):19798-19803.
24. Harper A.L., Meckes D.G., Marsh J.A., Ward M.D., Yeh P.C., Baird N.L., Wilson C.B., Semmes O.J., Wills J.W. Interaction domains of the UL16 and UL21 tegument proteins of herpes simplex virus. J. Virol. 2010, 84(6):2963-2971.
25. Higgins D.E., Shastri N., Portnoy D.A. Delivery of protein to the cytosol of macrophages using Escherichia coli K-12. Mol. Microbiol. 1999, 31(6):1631-1641.
26. Hill A., Jugovic P., York I., Russ G., Bennink J., Yewdell J., Ploegh H., Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995, 375(6530):411-415.
27. Hosken N., McGowan P., Meier A., Koelle D.M., Sleath P., Wagener F., Elliott M., Grabstein K., Posavad C., Corey L. Diversity of the CD8+ T-Cell response to Herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 2006, 80(11):5509-5515.
28. Hu P.Q., Tuma-Warrino R.J., Bryan M.A., Mitchell K.G., Higgins D.E., Watkins S.C., Salter R.D. Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC. J. Immunol. 2004, 172(3):1595-1601.
29. Hutchinson L., Browne H., Wargent V., Davis-Poynter N., Primorac S., Goldsmith K., Minson A.C., Johnson D.C. A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J. Virol. 1992, 66:2240-2250.
30. Jing L., Haas J., Chong T.M., Bruckner J.J., Dann G.C., Dong L., Marshak J.O., McClurkan C.L., Yamamoto T.N., Bailer S.M., Laing K.J., Wald A., Verjans G.M.G.M., Koelle D.M. Cross-presentation and genome-wide screening reveal candidate T cell antigens for a herpes simplex virus type 1 vaccine. J. Clin. Investig. 2012, 122:654-673.
31. Johnston C., Zhu J., Jing L., Laing J.K., McClurkan C.M., Klock A., Diem K., Jin L., Stanaway J., Tronstein E., Kwok W.W., Huang M.-L., Selke S., Fong Y., Margaret A., Koelle D.M., Wald A., Cory L. Virologic and immunologic evidence of multi-focal genital herpes simplex virus 2 infection. J. Virol. 2014, 88:4921-4931.
32. Karttunen J., Sanderson S., Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(13):6020-6024.
33. Kim M., Taylor J., Sidney J., Mikloska Z., Bodsworth N., Lagios K., Dunckley H., Byth-Wilson K., Denis M., Finlayson R., Khanna R., Sette A., Cunningham A.L. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J. Immunol. 2008, 181:6604-6615.
34. Koelle D.M. Expression cloning for the discovery of viral antigens and epitopes recognized by T cells. Methods 2003, 29:213-226.
35. Koelle D.M., Chen D.B., Gavin M.A., Wald A., Kwork W.W., Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 2001, 166:4049-4058.
36. Koelle D.M., Corey L. Recent progress in Herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 2003, 16(1):96-113.
37. Koelle D.M., Frank J.M., Johnson M.L., Kwok W.W. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 1998, 72(9):7476-7483.
38. Koelle D.M., Reymond S.N., Chen H., Kwok W.W., McClurkan C., Gyaltsong T., Petersdorf E.W., Rotkis W., Talley A.R., Harrison D.A. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J. Virol. 2000, 74(23):10930-10938.
39. Koelle D.M., Schomogyi M., McClurken C.M., Reymond S.N., Chen H.B. CD4 T cell responses to herpes simplex virus type 2 major capsid proteins VP5: comparison with responses to tegument and envelope glycoproteins. J. Virol. 2000, 74:11422-11425.
40. Laing K.J., Dong L., Sidney J., Sette A., Koelle D.M. Immunology in the clinic review series; focus on host responses: T cell responses to herpes simplex viruses. Clin. Exp. Immunol. 2012, 167(1):47-58.
41. Li Y., Gierahn T., Thompson C.M., Trzcinski K., Ford C.B., Croucher N., Gouveia P., Flechtner J.B., Malley R., Lipsitch M. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog. 2012, 8(11):e1002989.
42. Looker K.J., Garnett G.P. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex. Transm. Infect. 2005, 81(2):103-107.
43. Loomis J.S., Bowzard J.B., Courtney R.J., Wills J.W. Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J. Virol. 2001, 75(24):12209-12219.
44. Mascola J.R. Herpes simplex virus vaccines--why don[U+05F3]t antibodies protect?. JAMA 1999, 282(4):379-380.
45. Moffitt K.L., Gierahn T.M., Lu Y.-j., Gouveia P., Alderson M., Flechtner J.B., Higgins D.E., Malley R. TH17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9(2):158-165.
46. Morrison L.A., Zhu L., Thebean L.G. Vaccine -induced serum immunoglobulin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J. Virol. 2001, 75:1195-1204.
47. Moutaftsi M., Pasquetto V., Tscharke D.C., Sidney J., Bui H.-H., Grey H., Sette A. A consensus epitope prediction approach identifies the breath of murine T (CD8+)-cell responses in vaccinia virus. Nat. Biotechnol. 2006, 24:817-819.
48. Nakanishi Y., Lu B., Gerard C., Iwasaki A. CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 2009, 462(7272):510-513.
49. 4T cells. J. Immunol. 2014, 192:3730-3739.
50. Peng T., Ponce-de-Leon M., Jiang H., Dubin G., Lubinski J.M., Eisenberg R.J., Cohen G.H. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J. Virol. 1998, 72:65-72.
51. Picard M.D., Cohane K.P., Gierahn T.M., Higgins D.E., Flechtner J.B. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 2012, 30(29):4387-4393.
52. Posavad C.M., Remington M., Mueller D.E., Zhao L., Magaret A.S., Wald A., Corey L. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J. Immunol. 2010, 184(6):3250-3259.
53. Posavad C.M., Wald A., Hosken N., Huang M.L., Koelle D.M., Ashley R.L., Corey L. T cell immunity to herpes simplex viruses in seronegative subjects:silent infection or acquired immunity. J. Immunol. 2003, 170:4380-4388.
54. Radford K.J., Higgins D.E., Pasquini S., Cheadle E.J., Carta L., Jackson A.M., Lemoine N.R., Vassaux G. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther. 2002, 9(21):1455-1463.
55. Roan N.R., Gierahn T.M., Higgins D.E., Starnbach M.N. Monitoring the T cell response to genital tract infection. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(32):12069-12074.
56. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., Rammensee H.G. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 1991, 21:2891-2894.
57. Sette A., Sidney J. Nine major HLA class 1 supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenicis 1999, 50:201-212.
58. Shastri N., Gonzalez F. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol. 1993, 150(7):2724-2736.
59. Sidney J., Peters B., Frahm N., Brander C., Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008, 9(1):1.
60. Skoberne M., Cardin R., Lee A., Kazimirova A., Zielinski V., Garvie D., Lundberg A., Larson S., Bravo F.J., Bernstein D.I., Flechtner J.B., Long D. An adjuvanted herpes simplex virus type 2 (HSV-2) subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J. Virol. 2013, 87:3930-3942.
61. Spear P.G. Herpes simplex virus:receptors and ligands for cell entry. Cell. Microbiol. 2004, 6:401-410.
62. Spruance S.L., Evans T.G., McKeough M.B., Thai L., Araneo B.A., Daynes R.A., Mishkin E.M., Abramovitz A.S. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antivir. Res. 1995, 28(1):39-55.
63. Starnbach M.N., Loomis W.P., Ovendale P., Regan D., Hess B., Alderson M.R., Fling S.P. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J. Immunol. 2003, 171:4742-4749.
64. Szabo T.G., Palotai R., Antel P., Tokatly I., Tothfalusi L., Lund O., Nagy G., Faly A., Buzas E.I. Critical role of glycosylation in determining the length and structure of T cell epitopes. Immunome Res. 2009, 5:4.
65. Taylor J.M., Lin E., Susmarski N., Yoon M., Zago A., Ware C.F., Pfeffer K., Miyoshi J., Takai Y., Spear P.G. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2007, 2:19-28.
66. Teschner D., Wenzel G., Distler E., Schnürer E., Theobald M., Neutauter A.A., Schetne K., Herr W. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads. Scand. J. Immunol. 2011, 74:155-164.
67. Thebeau L.G., Morrison L.A. Mechanism of reduced T cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation. J. Virol. 2003, 77:2426-2435.
68. Wagner L.M., Bayer A., Deluca N.A. Requirement of the N-terminal activation domain of herpes simplex virus ICP4 for viral gene expression. J. Virol. 2013, 87(2):1010-1018.
69. Wagner L.M., Lester J.T., Sivrich F.L., DeLuca N.A. The N terminus and C terminus of herpes simplex virus 1 ICP4 cooperate to activate viral gene expression. J. Virol. 2012, 86(12):6862-6874.
70. Ward P.L., Barker D.E., Roizman B. A novel herpes simplex virus 1 gene, UL43.5 maps antisense to the UL43 gene and encodes a protein which colocalizes in nuclear structures with capsid proteins. J. Virol. 1996, 70:2684-2690.
71. Whitley R.J., Levin M., Barton N., Hershey B.J., Davis G., Keeney R.E., Whelchel J., Diethelm A.G., Kartus P., Soong S.J. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J. Infect. Dis. 1984, 150(3):323-329.
72. Zhu J., Koelle D.M., Cao J., Vazquez J., Huang M.L., Hladik F., Wald A., Corey L. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 2007, 204(3):595-603.
73. Zhu J., Peng T., Johnston C., Phasouk K., Kask A.S., Klock A., Jin L., Diem K., Koelle D.M., Wald A., Robins H., Corey L. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature 2013, 497(7450):494-497.